A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

计划入组 75 人 · 首次发布于 2014 年 4 月 25 日

AZD7451 for Recurrent Gliomas

计划入组 14 人 · 首次发布于 2011 年 11 月 9 日

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

计划入组 13 人 · 首次发布于 2021 年 5 月 10 日

ABP-1119

Trk A kinase inhibitors (Cephalon)

TRK-720

Corvus Pharmaceuticals

United States

Kura Oncology

United States

Odyssey Therapeutics

Vcare PharmaTech's Next-Generation TRK Inhibitor Eratrectinib Wins NMPA Approval for NTRK Fusion-Positive Solid Tumors

InnoCare's Next-Generation TRK Inhibitor Zurletrectinib Receives NMPA Approval in China for NTRK Fusion-Positive Solid Tumors

Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers